Alnylam Pharmaceuticals ALNY Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $502.34M+80.6% | $278.1M+236% | $82.79M+130% | -$279.86M-21.4% | -$230.47M+17.1% | ||
| $54.81M-1.5% | $55.66M-1.2% | $56.32M-0.3% | $56.5M-1.8% | $57.56M+1.6% | ||
| $361.68M+3.9% | $348.24M-5.4% | $368.25M+20.4% | $305.84M+7.9% | $283.45M+4.2% | ||
| —— | —— | $603.72M+151% | $240.95M+155% | $94.39M+9.1% | ||
| —— | —— | -$23.18M+3.9% | -$24.13M-22.0% | -$19.78M-45.6% | ||
| —— | —— | —— | —— | —— | ||
| $98.06M-21.2% | $124.5M+341% | $28.23M+79.1% | $15.77M+134% | -$45.92M-1,322% | ||
| —— | —— | —— | -$58.56M-13.0% | -$51.83M-32.9% | ||
| -$27.25M+48.5% | -$52.94M+19.5% | -$65.75M-16.7% | -$56.34M+75.9% | -$234.2M+0.5% | ||
| —— | —— | —— | -$4.04M+0.4% | -$4.06M-34.2% | ||
| $714.9M+36.4% | $524.08M+97.1% | $265.86M+1,811% | -$15.54M+67.0% | -$47.11M-467% | ||
| $71.56M+21.9% | $58.7M+31.9% | $44.5M+21.8% | $36.55M+20.7% | $30.27M-11.7% | ||
| $1.17B-10.7% | $1.31B-16.1% | $1.56B-12.5% | $1.78B+10.0% | $1.62B-1.1% | ||
| $334.18M-29.4% | $473.5M+12.6% | $420.59M+480% | -$110.77M— | —— | ||
| $213.82M-14.5% | $250.03M+2.2% | $244.61M-11.0% | $274.9M-15.8% | $326.46M+7.8% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | -$319.51M-238% | $231.59M-25.6% | $311.33M+5.8% | ||
| —— | —— | —— | $39.39M+350% | $8.76M+157% | ||
| $690.17M0.0% | $690.16M— | —— | —— | —— | ||
| $213.98M-2.2% | $218.71M+85.8% | $117.72M+7.0% | $109.97M+4.2% | $105.56M+56.2% | ||
| —— | —— | —— | —— | $15.34M+6.8% | ||
| —— | —— | —— | -$4.04M+0.4% | -$4.06M-34.2% | ||
| $98.06M-21.2% | $124.5M+341% | $28.23M+79.1% | $15.77M+134% | -$45.92M-1,322% | ||
| —— | $238.4M+13.2% | $210.58M+15.2% | $182.77M+18.0% | $154.95M+21.9% | ||
| —— | —— | $147.6M+7.4% | $137.46M-8.5% | $150.19M+18.1% | ||
| $59.78M0.0% | $59.78M— | —— | —— | —— | ||
| $213.82M-14.5% | $250.03M+2.2% | $244.61M-11.0% | $274.9M-15.8% | $326.46M+7.8% | ||
| —— | $6M+33.3% | $4.5M+50.0% | $3M+100% | $1.5M— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | $3.28M— | ||
| $15.05M-74.8% | $59.78M0.0% | $59.78M-22.6% | $77.28M-10.1% | $85.93M+11.5% | ||
| $12.66M-43.7% | $22.48M+64.5% | $13.67M+16.2% | $11.77M-37.4% | $18.78M+93.0% | ||
| —— | —— | —— | —— | $15.34M+6.8% | ||
| $643.34M+38.2% | $465.38M+110% | $221.36M+525% | -$52.09M+32.7% | -$77.38M-81.7% | ||
| $643.34M+38.2% | $465.38M+110% | $221.36M+525% | -$52.09M+32.7% | -$77.38M-81.7% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Alnylam Pharmaceuticals generate?
- Alnylam Pharmaceuticals (ALNY) generated $714.9M in operating cash flow over the trailing twelve months.
- What is Alnylam Pharmaceuticals's free cash flow?
- After $71.6M of capital expenditures, Alnylam Pharmaceuticals's free cash flow was $643.3M over the trailing twelve months, up 931.4% year over year.
- Where does Alnylam Pharmaceuticals's cash flow data come from?
- Every line is extracted from Alnylam Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
